Information Provided By:
Fly News Breaks for June 24, 2019
ANAB
Jun 24, 2019 | 08:32 EDT
SunTrust analyst Joon Lee maintained a Buy rating on Anaptys Bio but lowered his price target to $93 from $125 after a competitor drug with the same target as etokimab failing to meaningfully differentiate from dupilumab. However, the analyst still views etokimab as a viable drug in markets large enough to sustain multiple drugs.
News For ANAB From the Last 2 Days
There are no results for your query ANAB